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Abstract: To examine the prognosis of patients who present with very advanced HIV-induced immunodeficiency, and 
their response to highly active antiretroviral therapy (HAART), a series of 101 treatment naïve patients from the Serbian 
cohort of HIV infected patients, who presented with a CD4 count of  50/L before commencing HAART, was 
retrospectively analyzed and factors influencing response to HAART and survival investigated. After a mean of three 
years (range 1-9) of treatment with PI-based and/or NNRTI-based regimens, a favorable response was achieved in 54.5% 
of the patients, treatment failure occurred in 13.9%, while 31.7% had a dissociative immunological/virological response. 
The overall estimated survival was eight years. Achievement of undetectable viremia during treatment appeared life 
saving (OR = 42.5, 95% CI 7.1 – 251.9, P = 0.000, as was a rise in CD4 cell count to over 200/μL (OR = 6.4, 95% CI 1.2-
31.8, P = 0.023). However, undetectable viremia was the single predictor of longer survival (OR = 42.5, 95% CI 7.1 – 
251.9, P = 0.000), regardless of the level of immune reconstitution (log rank, P = 0.31). Late presenters had a high 
probability of developing the metabolic syndrome while on HAART, with a median time to hyperlipidemia and 
lypodystrophy of 5 and 6 years, respectively. We conclude that late presenters on HAART may have a good prognosis, a 
prerequisite for which is sustained undetectable viremia regardless of the immune recovery. 
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INTRODUCTION 
  A major advance in HIV disease treatment occurred with 
the introduction of highly active antiretroviral treatment 
(HAART) in 1996. HAART regimens comprise two 
nucleoside reverse transcriptase inhibitors (NRTIs) and a 
HIV protease inhibitor (PI) or non-nucleoside reverse 
transcriptase inhibitor (NNRTI), potent enough for complete 
and prolonged cessation of viral replication to allow 
reconstitution of the immune system [1-3]. Although both 
NRTIs and NNRTIs inhibit reverse transcriptase, their action 
through different mechanisms (NRTIs are phosphorylated to 
active metabolites and compete for incorporation into viral 
DNA, terminating synthesis of DNA chains, while NNRTIs 
bind directly to the reverse transcriptase enzyme active site) 
provides an enhanced effect. Immune recovery has even 
been achievable in severely ill patients. An overall reduction 
in late stage complications of HIV infection was associated 
with an impressive improvement in patient survival and 
quality of life [4-6]. However, we still do witness late 
presenters i.e. patients diagnosed with HIV infection in the 
advanced stage of HIV-related immunodeficiency, when 
they often suffer life-threatening opportunistic infections 
and/or tumors [7-12]. Most pertinent research investigated 
reasons for late presentation, while some also addressed the 
prognosis of late presenters on HAART [5-16]. 
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  Serbia is a country of low AIDS prevalence, with, 
however, a low HIV-testing rate. This is why a number of 
patients present late in the course of HIV disease. Indeed, 
between January 1998 and December 2007, late presenters 
have accounted for 17.1% of patients referred to the national 
HIV/AIDS Centre. We conducted a retrospective analysis of 
late presenters in whom HAART was initiated to study the 
factors influencing response to treatment and survival. 
METHODS 
Patients 
  The study series involved 101 treatment naïve patients 
from the Serbian cohort of HIV infected patients treated at 
the HIV/AIDS Centre at the Institute for Infectious and 
Tropical Diseases in Belgrade, who presented between 
January 1998 and December 2007 with most advanced HIV-
induced immunodeficiency. Inclusion criteria consisted of 
adult HIV infection (stages A-C according to the 1993 
Centers for Disease Control case definition criteria) [17], 
CD4 cell count below 50/L
  (“late presenters”), and 
initiation on HAART after diagnosis. Follow-up was 
continued until the last visit, death or 31 December 2007. 
Patients who did not survive the index AIDS defining 
condition were excluded from the study. Consent for 
participation was obtained from all, and the study was 
approved by the Clinical Centre of Serbia Ethics Committee. 
  Demographic characteristics, AIDS diagnosis prior to 
HAART initiation, co-infection with hepatitis C virus 
(HCV), along with parameters associated with response to 
HAART including plasma viral load and CD4+ cell count as Survival of Late Presenters on HAART  The Open Virology Journal, 2009, Volume 3    85 
well as the duration of treatment, were all assessed as 
variables with possible influence on treatment efficacy and 
survival. Influence of antiretroviral drug classes used as 
HAART components was also analyzed. 
Clinical and Laboratory Data 
  The immunological and virological responses to HAART 
were evaluated by measuring plasma viral load (pVL) and 
CD4+ T cell counts. Criteria for the type of response to 
HAART were as follows: the response was considered 
favorable in case of achievement of a sustained pVL 
reduction to undetectable values, along with CD4 cell count 
increases to above 200/L. In contrast, treatment failure was 
defined as a pVL over 2.9 log10 copies of HIV RNA/ml of 
plasma regardless of immunological improvement. In 
addition to these two clear-cut types of response to HAART, 
dissociation between immunological and virological 
responses to HAART occurred at times, defined as 
achievement of undetectable viremia during treatment but 
without a rise in CD4 cell counts to above 200/L [18, 19]. 
The threshold of 200 CD4 cells/L was taken as one decrea-
sing the risk of serious opportunistic infections. However, 
the results were additionnally analyzed according to a 
threshold of CD4 > 400 cells/L, which is one approaching 
normal values, and has been used in previous analyses of our 
cohort [19]. 
Laboratory Methods 
  CD4 cell counts and viral loads were measured in 
peripheral blood samples drawn at presentation and every 4-
6 months during follow-up. CD4 cells were quantified by 
flow cytometry. Plasma HIV-1 RNA loads were measured 
by a quantitative reverse transcriptase polymerase chain 
reaction (Roche Molecular Systems, Branchburg, NY, USA), 
which has a lower limit of detection of 50 copies/mL (1.7 
log10). 
Statistics 
  All analyses were performed using an electronic database 
organized in the SPSS (version 11.5) statistical package. The 
association between the type of response to HAART, and 
variables including baseline and end-point CD4 cell counts 
and pVL, type of HAART regimen, and age above 40, were 
assessed using the chi-square test and univariate and 
multivariate logistic regression. Odds ratios (ORs) and the 
corresponding 95% confidence intervals (CIs) were used as 
estimators of relative risk for HAART failure, and/or lethal 
outcome. The Kaplan-Meier product limit method was used 
to determine the probability of reaching immunological and 
virological improvement, and survival, as well as to assess 
the probability of developing drug toxicities over time. One-
way analysis of variance (ANOVA) was used to compare 
means. The level of statistical significance was 0.05. 
RESULTS 
Patient and Treatment Characteristics 
  Baseline characteristics of all patients are presented in 
Table 1. 
  Late presenters were more likely to be male (72.3%). 
Regarding transmission risk factors, the frequency of men 
having sex with men (MSM), heterosexuals and IV drug 
users was similar. There was only one patient who got 
infected vertically. 
Table  1.  Baseline Characteristics of a Series of 101 Late 
Presenters 
 
Variable N  (%) 
Female   28 (27.7) 
Male 73  (72.3) 
Age 44±9.8 
Risk Group 
 MSM 
 heterosexuals 
 IVDU 
 vertical  transmission 
 
43 (42.6)  
28 (27.7) 
29 (28.7) 
1 
Age over 40  57 (56.4) 
Clinical AIDS 
AIDS Defining Condition 
 TB 
 PCP 
 CE 
 WS 
 CNM 
 TGE 
 CMV 
 ADC 
 KS 
71 (70.3) 
 
23 (32.4) 
15 (21.1) 
10 (14.1) 
9 (12.7) 
4 (5.6) 
4 (5.6) 
3 (4.2) 
2 (2.8) 
1 (1.4) 
CD4 count/l (mean ± SD)  26.3±18.0 
HCV co-infection  32 (31.6) 
Men having sex with men (MSM); Intravenous drug users (IVDU); TB (Tuberculosis); 
PCP (P. carinii pneumonia); CE (Candida esophagitis); WS (Wasting syndrome); 
CNM (C. neoformans meningitis); TGE (Toxoplasma gondii encephalitis); CMV 
(Cytomegalovirus disease); ADC (AIDS dementia complex); KS (Kaposi sarcoma) 
 
  Treatment characteristics are presented in Table 2. The 
overall duration of HAART was 2.86 ± 1.80 years (range 1-
9), but varied according to regimen. HAART regimens 
included combinations of two NRTIs as a treatment 
backbone, with (I) one or two PI (taken by 34.6% of all 
patients), (II) one NNRTI (35.6%), and (III) combinations of 
drugs from all three classes or triple NRTI regimens during 
some period of their treatment (29.7% switched multiple 
regimens during follow-up). Regimen sequencing was 
performed in case of virological and/or immunological 
failure, and also in some instances to simplify treatment by 
lowering pill burden. Antiretrovirals available in Serbia 
included zidovudine (AZT), lamivudine (3TC), didanosine 
(ddI), stavudine (d4T), abacavir (ABV), nevirapine, 
efavirenz, indinavir, saquinavir, nelfinavir, lopinavir/r, 
ritonavir(r), and enfuvirtide. Ritonavir was used for PI 
boosting only. Genotypic resistance testing was not routinely 
performed; thus, subsequent regimens were composed on the 
basis of standards of care [20]. However, three extensively 
pre-treated patients, after being diagnosed with multi drug-
classes’ resistant virus, were switched to newer drugs, such 
as enfuvirtide, darunavir/r, and atazanavir/r (the latter two as 
a compassionate treatment). 
 86    The Open Virology Journal, 2009, Volume 3  Jevtovi et al. 
Table 2.  Characteristics of HAART in a Series of 101 Late 
Presenters 
 
Variable  No. of Patients  
(%) 
Duration of 
HAART  
Overall   101  2.9 ± 1.8 
PI based regimens   35 (34.65)  2.5 ± 1.5 
NNRTI based regimens   36 (35.64)  2.2 ± 1.4 
Multiple switching regimens   30 (29.7)  3.8 ± 2.3 
 
TREATMENT EFFICACY 
  A favorable response to HAART was achieved in 55 
(54.5%), a virological / immunological dissociation occurred 
in 32 (31.7%), while treatment failure was recorded in 14 
(13.9%) patients (Table 3A). The mean number of drugs 
needed to achieve a favorable response was 4.8 ± 2.1 (range 
3-10), similar (P > 0.05) to the number of drugs taken by 
those with HAART failure (5.0 ± 1.1) and a dissociative 
response (5.0 ± 1.5). 
  Gender, age over 40, and HIV transmission risk factor 
were not associated with HAART failure, nor was clinical 
AIDS at presentation (P  > 0.05). Moreover, no specific 
AIDS-defining condition affected the type of response to 
HAART (P = 0.33), nor did any specific treatment regimen, 
whether PI- or NNRTI-based. 
  Ten (9.9%) patients died during the follow-up period. 
The most frequent causes of death were AIDS-related 
conditions including PML, TB, ADC, and disseminated 
CMV disease in two cases each, while non-Hodgkin 
lymphoma and end-stage HCV-related liver disease were the 
causes of death in one patient each. Of those with a fatal 
outcome, eight patients (80%) experienced HAART failure, 
and two (20%) had a dissociative response to HAART. 
  The overall estimated survival was eight years (Table 
3B). Analysis of factors associated with survival showed that 
gender, age over 40, HIV disease stage, and HCV co-
infection did not affect survival (P > 0.05), nor did specific 
AIDS-defining conditions. Survival was also unaffected by 
treatment regimen, whether PI- or NNRTI-based (P = 0.66). 
However, the achievement of undetectable viremia 
regardless of the degree of immune recovery was a predictor 
of longer survival (Figs. 1, 2). For patients with a mean viral 
load of 1.7 ± 0.23 (1.7 – 1.9), the estimated survival was 8.7 
years, significantly longer (P < 0.001) than in those with a 
mean viral load of 3.6 ± 0.82 (2.9 – 5.2), whose estimated 
survival was 4.5 years. Achievement of undetectable viremia 
during treatment appeared life saving (OR = 42.5, 95% CI 
7.1 – 251.9, P = 0.000), as was as a CD4 cell count of above 
200/μL recorded in 57 (56.4%) patients (OR = 6.4, 95 CI 
1.2-31.8,  P = 0.023). The estimated survival in late 
presenters who achieved a rise in the CD4 cell count to 
above 200/μL was 8.7 years, as opposed to 5.8 years in those 
whose CD cell count did not recover to this level (P = 0.006) 
(Fig. 2). Interestingly, a CD4 count rise to over 400 cells/μL 
provided no extra benefit (P = 0.31, log rank). However, as  
 
revealed by multivariate logistic regression, achievement of 
undetectable viremia was the single independent predictor of 
survival (OR = 42.5, 95% CI 7.1 – 251.9, P = 0.000). 
Table  3A.   The Outcome of HAART in a Series of 101 Late 
Presenters 
 
Variable No.  (%) 
Treatment efficacy 
  CD4 count / L (mean ± SD)  265 ± 198 
 PVL  (log10) (mean ± SD)  1.9 ± 0.6 
 Undetectable  (pVL   2.0 log10) 87  (86.1) 
  Favorable response   55 (54.5) 
  Failure   14 (13.9) 
  Virological / immunological dissociation 
Adverse events 
 IRD 
 Severe  heptotoxicity 
 Lipodystophy 
 Hyperlipidemia 
32 (31.7) 
 
11 (10.9) 
2 (1.9) 
31 (30.6) 
58 (57.4) 
 
Table 3B.  The Estimated Probability of Survival in a Series of 
101 Late Presenters (Kaplan Meier) 
 
 Years  P 
Variable (Yes / No) 
 Undetectable  viremia 
  CD cell count rose to >200/μL 
8.7 / 4.5 
8.7 / 5.8 
0.00 
0.00  
HAART- related survival 
  Only PI-based regimens 
  Only NNRTI-based regimens 
8.1 
5.3 
0.66 
 
  Immune restoration disease (IRD) developed in 11 
(10.9%) patients, at a mean CD4 cell count of 270.4 ± 131.0. 
Dermatomal herpes zoster was the leading IRD 
manifestation, appearing in six patients. Other IRD 
presentations included CMV vitritis, genital herpes, TB, 
cryptococcal meningitis and a hepatitis flare in an HCV co-
infected patient. The metabolic syndrome occurred 
frequently during treatment of late presenters. Hyper-
lipidemia and lipodystrophy were recorded in 58 (7.4%) and 
31 (30.6%) patients, respectively. Type 2 diabetes mellitus 
was recorded in 8 (7.9%). The median time to develop 
hyperlipidemia and lipodystrophy was 5 and 6 years, 
respectively. The 9-year probability of developing 
hyperlipidemia and lipodystrophy was 100%, while it was 
30% for type 2 diabetes mellitus. 
DISCUSSION 
  According to the results on the efficacy of HAART in 
our series of late presenters, these severely immunodeficient 
patients may have a rather good prognosis. Those who 
initiated HAART during or after recovering from 
opportunistic infections had a similar life expectancy as   
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Fig. (1). Estimated probability of survival of late presenters 
according to achievement of undetectable viremia. pVL  2 log10 
___ , pVL  3log10 ----- , P = 0.009. 
 
Fig. (2). Estimated probability of survival of late presenters 
according to achievement of CD4 cell coubt above 200/μL during 
HAART. Achieved ___ , not achieved ----- , P = 0.00. 
asymptomatic patients. Specific opportunistic events did not 
predict the outcome. If patients who commence HAART at a 
most advanced stage of HIV disease achieve undetectable 
viremia, they may have a very good prognosis even if the 
immune system has not recovered to the most desirable CD4 
cell counts. Sabin et al. reported a 13% mortality among late 
presenters after a follow-up of 2.5 years [7]. If the results in 
our patient series are analyzed for this period, the mortality 
rate is quite similar (15.5%, data not shown). And moreover, 
since after a mean follow up of 2.9 ± 1.8 years the mortality 
rate dropped to 9.9%, HAART efficacy seems to increase 
over time. Hocking et al. suggested that increased survival of 
late presenters with AIDS on HAART may indicate a 
positive response of drug naive patients to antiretroviral 
therapies [6]. 
  Using the life expectancy model for the prognosis of 
HIV/AIDS in the HAART era, the ART Cohort 
Collaboration study reported a 8.5% mortality rate for 
patients who initiated HAART at a CD4 cell count below 
50/L [5, 6]. Even in the high income countries analyzed by 
the ART Cohort Collaboration study, late presentation had 
emerged as an issue of concern, since nearly one half of 
patients started HAART either with a CD4 cell count of less 
than 200 cells/ L or with a diagnosis of AIDS. HIV 
management guidelines advocate early diagnosis and timely 
treatment. Such a strategy is essential to prevent clinical 
progression as well as the spread of the infection, in line with 
public health principles of wide screening and treatment 
shown to be effective in the control of many infectious 
diseases. The Centres for Disease Control and Prevention 
estimate that more than one half of new HIV infections are 
spread by HIV-positive individuals who are unaware of their 
infection, and thus support expanded, voluntary and cost-
effective screening in healthcare settings, on the basis of opt-
out strategy [21]. Wide voluntary screening in healthcare 
settings should be particularly advocated in Serbia, given 
that the HIV testing rate in Serbia is among the lowest in 
Europe. 
  Profound immunodeficiency on HAART initiation is 
associated with a risk of IRD. We, and others, have 
previously shown that a CD4 count below 100/L at 
HAART initiation is a major risk factor for the development 
of IRD during HAART [22, 23]. The overall prevalence of 
IRD among late presenters was 10.9 %, similar to our earlier 
data in the whole Serbian cohort of HIV/AIDS patients 
(16.7%) [22]. IRD strongly affects the patients’ quality of 
life, since these episodes often require hospital admissions. 
Hyperlipidemia and lipodystrophy also emerged as important 
issues among late presenters on HAART, with an increased 
incidence as compared to the whole cohort [24]. 
  Taken together, the presented results on HAART efficacy 
in late presenters indicate that reaching and maintaining 
undetectable viremia is a prerequisite for good prognosis for 
late presenters on HAART, regardless of the level of 
immune recovery. 
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